New vaccine aims to shield against multiple sarbecoviruses
NCT ID NCT07280858
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 13 times
Summary
This study tests a new vaccine called GBP511, designed to protect against a family of viruses called sarbecoviruses (which includes SARS-CoV-2). Researchers want to see if it is safe and triggers a strong immune response in healthy adults aged 18 and older. The trial involves up to 368 participants and compares different doses, with or without an adjuvant to boost effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linear
NOT_YET_RECRUITINGJoondalup, Western Australia, 6027, Australia
Contact
-
Linear
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.